In addition, you must meet one of the three clinical criteria set by CMS, measured at the time you start GLP-1 therapy: BMI of 35 or higher (and age 18 or older), or BMI of 30 or higher (and age 18 or older), plus one of the following: heart failure with preserved ejection fraction, uncontrolled high blood pressure (systolic above 140 or diastolic above 90 despite treatment with two blood pressure medications), or chronic kidney disease stage 3a or above, or BMI of 27 or higher (and age 18 or older), plus one of the following: prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease If you take a GLP-1 for another condition, the Bridge is not for you
They work by helping your kidneys remove extra salt, improving how your blood vessels work, and promoting weight loss
Beyond glycemic control, these medications slow gastric emptying (though this effect may diminish over time), which prolongs the feeling of fullness after meals
(2017) 5:e13199
Collectively, these developments underscore the growing importance of GLP-1-related therapies as companies compete to address some of the worlds largest and fastest-growing chronic health challenges
